{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-21-000038","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.736373+00:00","generated_at":"2026-06-28T11:36:43.162983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Black Diamond Therapeutics Q3 2021 cash $235M; BDTX-189 Phase 2 on track for year-end","bullets":["Cash, equivalents, and investments $235.0M as of Sept 30, 2021; expected runway into H2 2023.","Net cash used in operations Q3 2021 was $26.5M, up from $11.5M in Q3 2020.","R&D expenses $27.6M (Q3 2021) vs $12.9M (Q3 2020), driven by headcount and preclinical/clinical costs.","BDTX-189 Phase 2 portion initiation by end of 2021; BDTX-1535 IND filing targeted H1 2022.","Preclinical data for BDTX-1535, BRAF, and FGFR programs presented at ANE conference; partnership with OpenEye Scientific."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-21-000038","json":"https://secwatch.observer/filing/0001701541-21-000038.json","markdown":"https://secwatch.observer/filing/0001701541-21-000038.md","text":"https://secwatch.observer/filing/0001701541-21-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154121000038/0001701541-21-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154121000038/bdtx-20211108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:36:43.162983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}